Off‑Target Risk
Prediction Service
Map plausible unintended targets, connect them with safety‑relevant biology, and prioritize the counter‑screens that can most efficiently de‑risk a lead series.
Off‑Target Risk Prediction Services
Select a focused module or combine them as an investigation that moves from an unexplained signal to a compact, justified counter-screen.
The workflow begins with the safety question or selectivity decision, not with a predefined modeling package.
Ligand‑ and Chemogenomic Off‑Target Search
Find plausible unintended targets using known ligand sets, bioactivity relationships, and multi‑task prediction. Target hypotheses, chemical evidence, coverage flags.
Focused Structure‑Based Screening
Use reverse docking or binding‑site modeling for suitable targets to provide orthogonal evidence, not a universal proteome score. Pose hypotheses, site compatibility, structure QC.
Target‑to‑Pathway and Phenotype Mapping
Prioritize interactions that are biologically and exposure relevant rather than ranking targets by model score alone. Safety‑target annotation, tissue/pathway context, ADR hypotheses.
Counter‑Screen Panel Design
Translate computational hypotheses into a concise validation panel that can support advance, redesign, or stop decisions. Assay priorities, comparator controls, decision thresholds.
Analog Series Promiscuity Comparison
Evaluate off‑target profiles across a chemical series to identify analogs with improved selectivity without sacrificing primary activity.
Adverse Effect Mechanism Hypotheses
Connect phenotypic observations with plausible target interactions and propose discriminatory experiments to confirm or reject the mechanism.
Custom Target Panel Modeling
Incorporate proprietary counter‑screen data into a project‑specific scoring model with assay‑aware curation and validation.
Start wide. Finish with a testable shortlist.
An off-target search may nominate hundreds of proteins. The useful work is the controlled narrowing: removing weak associations, adding tissue and exposure context, and preserving only hypotheses that can change a development decision.
Each funnel stage records why a target was retained or removed, producing an auditable counter-screen rationale rather than an unexplained ranked list.
Combine ligand, chemogenomic, binding-site, and known pharmacology evidence.
Filter by tissue access, expression, pathway relevance, and achievable free exposure.
Compare orthogonal support, uncertainty, assay artifacts, and analog-series consistency.
Select discriminatory targets, controls, concentration ranges, and stop/go criteria.
Investigate the mechanism behind an unwanted signal
Begin with the phenotype, organ concern, or selectivity gap—not with a generic target panel—and work backward to the evidence needed.
Signals that trigger an investigation
Orthogonal evidence and exposure‑weighted ranking to build a focused counter‑screen panel.
Target‑pathway‑phenotype hypothesis mapping with discriminatory experiments.
Series‑level off‑target and promiscuity comparison with selectivity tiers.
Target‑structure suitability and focused reverse screening with structure‑supported hypotheses.
Evidence strength + biological context to select the most informative next step.
Evidence assembled for each signal
Each response is chosen to discriminate among plausible mechanisms, reduce an oversized target list, and specify the next counter-screen.
Organize candidates by why they matter
A protein earns a place on the shortlist for a specific reason. These evidence dossiers keep hazard, biology, exposure, and structural similarity from collapsing into one opaque score.
Documented hazard
Proteins linked with cardiac, CNS, hepatic, or other organ‑system adverse effects.
Dossier basis: adverse-outcome evidencePromiscuous families
Groups known for promiscuity or off‑target liabilities (e.g., GPCRs, kinases, ion channels).
Dossier basis: family-wide binding historyMechanistic neighbors
Targets within the same biological pathways as the intended target.
Dossier basis: pathway proximityExposure-accessible tissue
Targets with high expression in relevant organs (heart, liver, brain, etc.).
Dossier basis: expression × distributionBinding-site mimics
Proteins with similar binding sites to the intended target.
Dossier basis: pocket resemblanceConnect chemistry and biology to safety decisions
Off‑target prediction spans ligand‑based similarity, chemogenomic models, structure‑based reverse screening, and biological context integration. Our platform combines these to provide ranked, evidence‑qualified hypotheses.
Each prediction is accompanied by the type and strength of supporting evidence, applicability flags, and a clear path to experimental validation.
Broad hypotheses are filtered by biological relevance and experimental feasibility before being promoted to the counter‑screen panel.
Compare compound structures with known target ligand sets to identify unexpected associations.
Multi‑task machine learning trained on bioactivity data across target families.
Fit compounds into target binding sites for suitable structures to provide orthogonal evidence.
Pathway, tissue, safety‑target, and adverse‑event mapping for each candidate target.
Combine scores, confidence, exposure context, and program criteria into a ranked panel.
Choose the investigation pattern that matches the signal
Each scenario begins with a different clue—selectivity loss, unexpected phenotype, analog drift, or proprietary evidence—and therefore demands a different path through target space.
Prioritize counter‑screens before lead nomination.
Target universe → orthogonal prediction → exposure‑weighted panel with evidence types and confidence flags.
Output: focused counter‑screen panel and validation rationale.Connect a cellular signal with plausible unintended targets.
Phenotype context → target mapping → pathway analysis → discriminatory assay proposals.
Output: mechanism hypotheses and experimental plan.Compare analog promiscuity and redesign options.
Series scoring → evidence ladder → chemistry priorities with structural modifications.
Output: selectivity tiers and redesign recommendations.Incorporate proprietary counter‑screen data.
Assay‑aware curation → model validation → project‑specific scoring and calibration.
Output: validated internal model and decision framework.From safety question to decision‑ready report
The investigation is configured around the observed signal, accessible target evidence, exposure assumptions, and the counter-screen threshold that will change the program's direction.
Define the Question
Identify the safety decision: triage, phenotype, selectivity, or panel design.
Curate Data
Structures, intended target, known pharmacology, exposure context, and program criteria.
Run Predictions
Apply ligand‑based, chemogenomic, and structure‑based methods to generate hypotheses.
Integrate Evidence
Combine prediction strength, biological relevance, exposure plausibility, and confidence.
Deliver Decision
Provide ranked panel, experimental plan, and redesign or confirmation priorities.
Results designed for development decisions
The final package combines ranked target hypotheses, biological context, confidence annotations, and a focused validation plan.
Compound‑target associations with evidence types and scores.
Evidence strength, applicability flags, data provenance, and uncertainty notes.
Pathway, tissue, safety‑target, and potential adverse‑effect mapping.
Analog‑series promiscuity and selectivity tiers.
Prioritized targets, controls, assay recommendations, and decision criteria.
Models, datasets, structures, plots, and documentation.
Planning an off‑target risk project
Does a predicted off‑target prove that a compound will cause an adverse effect?
No. Binding or activity must be confirmed, and clinical relevance depends on potency, free exposure, tissue distribution, pathway context, and compensatory biology.
How large should the target panel be?
The useful panel is decision‑dependent. Broad virtual screening can generate hypotheses, while a focused experimental panel should prioritize high‑evidence, exposure‑plausible, safety‑relevant targets.
Can reverse docking screen the whole proteome?
Proteome‑scale docking is limited by structure availability, binding‑site definition, scoring bias, protein flexibility, and compute. It is best used selectively and combined with ligand and bioactivity evidence.
Can peptides or biologics be assessed?
Yes, but the evidence sources, interaction models, and target universe differ from small molecules and should be scoped specifically for the modality.
How are unknown chemotypes handled?
Predictions with weak ligand support, poor model applicability, or unsuitable target structures are flagged as uncertain and are not promoted solely by a high score.
What information is needed to start a project?
Helpful inputs include structures, intended target, known pharmacology, exposure context, safety concerns, and the decision the study should support.
Which off‑targets matter for your program?
Send the structures, intended target, any unexpected assay or phenotype results, and the exposure range. CD ComputaBio will define a focused off-target investigation and validation panel.
Online Inquiry
Submit your project details below, and our team will respond within 24 hours.
Talk to our technical team about your project!
I Want To Talk